Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04005690 · ClinicalTrials.gov registry record · Early Phase 1
Targeted Pathway Inhibition in Patients With Pancreatic Cancer
A Early Phase 1 study of Stage IV Pancreatic Cancer AJCC v8 and Stage III Pancreatic Cancer AJCC v8, sponsored by OHSU Knight Cancer Institute.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 90
- Enrollment target
- 1
- Study location
NCT04005690 is a Early Phase 1 study of Stage IV Pancreatic Cancer AJCC v8 and Stage III Pancreatic Cancer AJCC v8 that is actively recruiting participants, run by OHSU Knight Cancer Institute. The registered enrollment target is 90 participants, roughly in line with the 86-participant average among 31 other Stage IV Pancreatic Cancer AJCC v8 trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT04005690, a Early Phase 1 study of Stage IV Pancreatic Cancer AJCC v8 and Stage III Pancreatic Cancer AJCC v8, is actively recruiting participants, sponsored by OHSU Knight Cancer Institute.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
This early phase I trial aims to determine how cobimetinib, olaparib, onvansertib, azenosertib, AZD5305 or tremelimumab works in patients with pancreatic cancer. Validation of cobimetinib, olaparib, onvansertib azenosertib, AZD5305 and tremelimumab molecular targets will be explored by comparing pre-treatment biopsies with post-treatment specimens. This knowledge will help design future biomarker driven trials to determine whether giving cobimetinib, or olaparib, or onvansertib or azenosertib, or AZD5305, or tremelimumab will work better than standard treatments in patients with pancreatic cancer.
Conditions Studied
Interventions
- DRUG Olaparib
- DRUG Azenosertib
- DRUG Onvansertib
- DRUG Cobimetinib
- DRUG Saruparib
Study Locations (1)
Oregon
- OHSU Knight Cancer Institute - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2019-08-01 |
| Est. Completion | 2028-02-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04005690
The ClinicalTrials.gov registry entry for NCT04005690 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 86-participant average among 31 other Stage IV Pancreatic Cancer AJCC v8 trials with a reported enrollment target. The listed sponsor is OHSU Knight Cancer Institute, which has 211 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Stage IV Pancreatic Cancer AJCC v8 appearing as the primary indexed condition, and to 5 interventions - of which Olaparib is the first listed.
NCT04005690 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.
Frequently Asked Questions
What is clinical trial NCT04005690 about?
NCT04005690 is a clinical study titled "Targeted Pathway Inhibition in Patients With Pancreatic Cancer". This early phase I trial aims to determine how cobimetinib, olaparib, onvansertib, azenosertib, AZD5305 or tremelimumab works in patients with pancreatic cancer. Validation of cobimetinib, olaparib, onvansertib azenosertib, AZD5305 and tremelimumab molecular targets will be explored by comparing pre...
What is the current status of trial NCT04005690?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 90 participants. The study started on 2019-08-01. Estimated completion is 2028-02-01.
What conditions does trial NCT04005690 study?
This clinical trial studies the following conditions: Stage IV Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Locally Advanced Pancreatic Ductal Adenocarcinoma.
What interventions are being tested in trial NCT04005690?
The interventions under investigation include: Olaparib (DRUG), Azenosertib (DRUG), Onvansertib (DRUG), Cobimetinib (DRUG), Saruparib (DRUG).
Who is sponsoring clinical trial NCT04005690?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04005690 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IV Pancreatic Cancer AJCC v8
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma
RECRUITING · Early Phase 1
-
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
RECRUITING · Phase 1
-
Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors
RECRUITING · Phase 1
-
Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer
RECRUITING · Phase 1
-
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
RECRUITING · Phase 1
-
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
RECRUITING · Phase 2
Explore more on PlainTrial
Stage IV Pancreatic Cancer AJCC v8
All registered trials for this condition
Stage III Pancreatic Cancer AJCC v8
All registered trials for this condition
Oregon
All trials with a study site in Oregon
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.